Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...
Zacks.com on MSN11h
LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II StudyEli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback